Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.35 |
| ▸ | KIF11 | P52732 | 1/20 | 0.35 |
| ▸ | TRPM4 | Q8TD43 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.34 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | NQO2 | P16083 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11073716 | 0.81 | BACE1 (0.47) | CYP1A2CYP2A6ALDH1A1HSD17B10HIF1A | |
| SCHEMBL20114651 | 0.81 | NR3C1 (0.38) | NR3C1NR3C2 | |
| SCHEMBL22967807 | 0.80 | CYP1A2 (0.43) | CYP1A2CYP2A6ALDH1A1TSHRTDP1 | |
| SCHEMBL24712674 | 0.79 | CYP1A2 (0.57) | CYP1A2CYP2A6ALDH1A1HSD17B10HIF1A | |
| SCHEMBL26579482 | 0.79 | CYP1A2 (0.39) | CYP1A2CYP2A6ALDH1A1HSD17B10HIF1A | |
| SCHEMBL23565161 | 0.79 | PTPN1 (0.39) | CYP1A2CYP2A6ALDH1A1HSD17B10HIF1A | |
| SCHEMBL21085333 | 0.78 | ALDH1A1 (0.37) | CYP1A2CYP2A6ALDH1A1HSD17B10HIF1A | |
| SCHEMBL17030753 | 0.78 | ALDH1A1 (0.40) | CYP1A2CYP2A6ALDH1A1HSD17B10HIF1A | |
| SCHEMBL2454488 | 0.78 | CYP2A6 (0.40) | CYP1A2CYP2A6ALDH1A1HSD17B10HIF1A | |
| SCHEMBL12401757 | 0.78 | CYP2A6 (0.40) | CYP1A2CYP2A6ALDH1A1HSD17B10HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030853-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2024-07-09 | — | — | US | disclosed |
| US-20230374036-A1 | KRAS G12D MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230374036-A1 | KRAS G12D MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230339981-A1 | KRAS G12D MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2023-10-26 | — | — | US | disclosed |
| US-20230339981-A1 | KRAS G12D MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2023-10-26 | — | — | US | disclosed |
| US-20230212183-A9 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2023-07-06 | — | — | US | disclosed |
| US-20230192668-A1 | ORGANIC COMPOUND, AND ELECTRONIC ELEMENT AND ELECTRONIC DEVICE THEREOF | SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) | 2023-06-22 | — | — | US | disclosed |
| US-20210317127-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF CANCER | ARAXES PHARMA LLC (US) | 2021-10-14 | — | — | US | disclosed |
| US-20210188869-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2021-06-24 | — | — | US | disclosed |
| US-10927125-B2 | Substituted cinnolines as inhibitors of KRAS G12C | ARAXES PHARMA LLC (US) | 2021-02-23 | — | — | US | disclosed |
| US-20200102321-A1 | SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2020-04-02 | — | — | US | disclosed |
| US-20190262342-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | ARAXES PHARMA LLC | 2019-08-29 | — | — | US | disclosed |
| US-20180118757-A1 | SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2018-05-03 | — | — | US | disclosed |
| US-9905776-B2 | Pyrene-based compound and organic light-emitting diode comprising the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2018-02-27 | — | — | US | disclosed |
| US-9840516-B2 | Substituted quinazolines as inhibitors of KRAS G12C | ARAXES PHARMA LLC (US) | 2017-12-12 | — | — | US | disclosed |
| US-9840516-B2 | Substituted quinazolines as inhibitors of KRAS G12C | ARAXES PHARMA LLC (US) | 2017-12-12 | — | — | US | disclosed |
| US-20160166571-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | ARAXES PHARMA LLC | 2016-06-16 | — | — | US | disclosed |
| US-20150239900-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2015-08-27 | — | — | US | disclosed |
| US-20140183468-A1 | PYRENE-BASED COMPOUND AND ORGANIC LIGHT-EMITTING DIODE COMPRISING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2014-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210188869-A1 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | CYP1A2 3408/4885CYP2A6 3163/4885ALDH1A1 4178/4885 |
| US-10927125-B2 | Substituted cinnolines as inhibitors of KRAS G12C | KRAS, NRAS, HRAS | CYP1A2 1836/4885CYP2A6 3522/4885ALDH1A1 2326/4885 |
| US-20230192668-A1 | ORGANIC COMPOUND, AND ELECTRONIC ELEMENT AND ELECTRONIC DEVICE THEREOF | XPO4, OR10J3, EPB41 | CYP1A2 721/4885CYP2A6 1658/4885ALDH1A1 2948/4885 |
| US-20200102321-A1 | SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | CYP1A2 1845/4885CYP2A6 2842/4885ALDH1A1 4009/4885 |
| US-20180118757-A1 | SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | CYP1A2 1845/4885CYP2A6 2842/4885ALDH1A1 4009/4885 |
| US-20150239900-A1 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | CYP1A2 3408/4885CYP2A6 3163/4885ALDH1A1 4178/4885 |
| US-20230212183-A9 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | CYP1A2 3408/4885CYP2A6 3163/4885ALDH1A1 4178/4885 |
| US-20190262342-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | KRAS, TP53, HRAS | CYP1A2 4679/4885CYP2A6 4567/4885ALDH1A1 1577/4885 |
| US-20230339981-A1 | KRAS G12D MODULATING COMPOUNDS | KRAS, NRAS, HRAS | CYP1A2 4742/4885CYP2A6 3882/4885ALDH1A1 4243/4885 |
| US-20230374036-A1 | KRAS G12D MODULATING COMPOUNDS | KRAS, NRAS, HRAS | CYP1A2 4742/4885CYP2A6 3882/4885ALDH1A1 4243/4885 |
| US-20210317127-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF CANCER | KRAS, NRAS, HRAS | CYP1A2 3192/4885CYP2A6 2215/4885ALDH1A1 1405/4885 |
| US-20160166571-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | KRAS, TP53, HRAS | CYP1A2 4679/4885CYP2A6 4567/4885ALDH1A1 1577/4885 |
| US-12030853-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | CYP1A2 4271/4885CYP2A6 4656/4885ALDH1A1 4709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.